Functionalized Polymer Nanoparticles for Targeted Intracellular Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current bioactive molecule delivery systems face challenges in efficiently transporting molecules into cells, particularly due to issues with nanoparticle size, biocompatibility, and specificity in interacting with cellular transporters like SLC22A4, SLC6A14, and SLC22A16, leading to variable bioavailability and therapeutic efficacy.
Innovation Solution
Development of biocompatible and biodegradable polymer nanoparticles derivatized with specific trialkylammonium radicals that interact with organic cationic transporters, allowing for efficient release of bioactive compounds within cells expressing these transporters, with a focus on achieving optimal size and charge for enhanced cellular uptake.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional polymeric nanoparticles are used for drug delivery, then biocompatibility is improved, but cellular internalization efficiency deteriorates
Solution Approach 1:
The patent modifies the surface charge parameter of polymeric nanoparticles by derivatizing them with cationic groups (ammonium, phosphonium, sulfonium radicals). This parameter change enables the nanoparticles to interact with and be internalized by cells expressing organic anion transporters, thereby improving cellular internalization efficiency while maintaining biocompatibility of the base polymer matrix.
Solution Approach 2:
The patent creates composite nanoparticles by combining biocompatible polymeric matrices (such as PLGA, chitosan, gelatin) with cationic functional groups. This composite structure integrates the biocompatibility of natural/synthetic polymers with the cell-penetrating capability of cationic moieties, resolving the contradiction between biocompatibility and internalization efficiency.
2Productivity
If nanoparticle size is reduced to enhance diffusion through biological barriers, then transcellular transport is improved, but manufacturing precision requirements worsen
Solution Approach 1:
The patent optimizes the size parameter of nanoparticles to a specific range (50-200 nm) that balances diffusion capability through biological barriers with manufacturing feasibility. This parameter optimization enables effective transcellular transport while maintaining controllable manufacturing precision using conventional nanoprecipitation and emulsion techniques.
3Productivity
If cationic groups are added to enhance interaction with cell membranes, then cellular uptake is improved, but cytotoxicity increases
Solution Approach 1:
The patent applies cationic functional groups locally on the nanoparticle surface rather than throughout the entire structure. This localized functionalization enables specific interaction with cell membranes and organic anion transporters for improved uptake, while the bulk biocompatible polymer matrix maintains low cytotoxicity.
Solution Approach 2:
The patent employs biodegradable polymeric materials that can be safely metabolized and eliminated by the body. This approach allows the use of cationic groups for enhanced cellular uptake while minimizing long-term cytotoxicity concerns, as the nanoparticle structure degrades into non-toxic byproducts after fulfilling its delivery function.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The derivatized polymer nanoparticles demonstrate improved bioavailability and therapeutic efficacy by efficiently delivering bioactive molecules into cells through specific interaction with SLC22A4, SLC6A14, and SLC22A16 transporters, achieving rapid and targeted drug delivery with high encapsulation efficiency and minimal cytotoxicity.
Implementation Method 1
Larger molecules enter cells with different mechanisms based on their ability to interact with the cell membrane due to surface charges before being internalized in general by endocytosis or by binding to surface structures that favor carrier-mediated transport to inside the cell
Data Source
Figure 1a~1b
Figure 1c
Figure 2a~2b
AI summary
This invention pertains to systems suitable for the intracellular release of bioactive compounds, such systems comprising a biocompatible and/or biodegradable polymer derivatized with radicals R, A, B or C described herein and their use for transporting bioactive compounds inside cells that express an organic cationic transporter, particularly SLC22A4, SLC6A14 e SLC22A16.